| Literature DB >> 32082931 |
Ali Ahmet Arıkan1, Selçuk Emre2, Bayraktar Fatih Avni2.
Abstract
Inferior vena cava agenesis is a rare anomaly which may result in deep vein thrombosis. There is no clear scientific evidence for the most effective therapeutic management, optimal duration, or the choice of anticoagulant therapy. Herein, we report an 18-year-old male case with deep vein thrombosis associated with inferior vena cava agenesis who was on rivaroxaban as a lifelong anticoagulation treatment for symptoms of venous stasis and the presence of heterozygotic thrombophilic mutations.Entities:
Keywords: Inferior; rivaroxaban; thrombophilia; vascular malformation; vein thrombosis; vena cava
Year: 2019 PMID: 32082931 PMCID: PMC7018169 DOI: 10.5606/tgkdc.dergisi.2019.17672
Source DB: PubMed Journal: Turk Gogus Kalp Damar Cerrahisi Derg ISSN: 1301-5680 Impact factor: 0.332